LILACS – Literatura Latinoamericana y del Caribe de Ciencias de la Salud

Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment

Blatt, Carine Raquel; Storb, Bernd; Mühlberger, Nikolai; Farias, Mareni Rocha; Siebert, Uwe.

Braz. j. pharm. sci; 50 (2), 2014

Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 24 weeks. The aim of this study is compare the cost and effectiveness to Hepatitis C treatment in pat...

Hepatitis C Crónica/clasificación, Terapéutica/economía, Genotipo, Análisis Costo-Beneficio/estadística & datos numéricos, Factor 2 Regulador del Interferón/clasificación, Factor 3 Regulador del Interferón, Costos y Análisis de Costo/clasificación

Fulltext

Poly-ε -caprolactone microspheres containing interferon alpha as alternative formulations for the treatment of chronic hepatitis C

Interferon-alpha (IFN-alpha) is one of the main drugs used in the treatment of hepatitis C. Use of IFN-alpha has some limitations that result in poor treatment efficacy and low patient compliance. Therefore, the aim of this study was to develop poly-ε-caprolactone (PCL) microspheres containing IFN-a...